KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Equity Income (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Equity Income for 9 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Income changed N/A year-over-year to $2.0 million, compared with a TTM value of -$500000.0 through Sep 2025, changed N/A, and an annual FY2025 reading of $15.0 million, up 1400.0% over the prior year.
  • Equity Income was $2.0 million for Q3 2025 at Teva Pharmaceutical Industries, up from -$500000.0 in the prior quarter.
  • Across five years, Equity Income topped out at $21.0 million in Q1 2022 and bottomed at -$5.0 million in Q3 2021.
  • Average Equity Income over 5 years is $2.2 million, with a median of $1.0 million recorded in 2022.
  • The sharpest move saw Equity Income soared 600.0% in 2022, then plummeted 900.0% in 2024.
  • Year by year, Equity Income stood at -$5.0 million in 2021, then soared by 120.0% to $1.0 million in 2022, then changed by 0.0% to $1.0 million in 2023, then skyrocketed by 100.0% to $2.0 million in 2024, then changed by 0.0% to $2.0 million in 2025.
  • Business Quant data shows Equity Income for TEVA at $2.0 million in Q3 2025, -$500000.0 in Q1 2025, and $2.0 million in Q2 2024.